Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

NCT03598309 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Lung Diseases
Lung Cancer, Protection Against

Interventions

DRUG: Curcumin C3 complex®
DRUG: Lovaza®
OTHER: Placebo

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]